Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

743.52 +5.69 (+0.77%)
Streaming Delayed Price Updated: 12:27 PM EDT, Sep 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Why Novo Nordisk Stock Slipped Today
The Danish pharmaceutical company is fighting a competitive war on several fronts. 
Via The Motley Fool
Topics Lawsuit
Is It Time to Buy Biotech Stocks?
A surge in private market investment has investors wondering: Is it time to bet bigger on biotech? 
Via The Motley Fool
RFK Jr. Sued By Eli Lilly, Amgen Over Drug Discount Program
Eli Lilly and Amgen are suing HHS over 340B certifications, claiming ineligible clinics cost them millions in lost revenue. 
Via Benzinga
Topics Lawsuit
LifeMD Stock Plummets 40%. Why Weight Loss Isn't Just A Gimme.
The company is struggling with several headwinds as it works to develop its obesity plan. 
Via Investor's Business Daily
Novo Nordisk Slumps As It Cautions 'Unsafe And Unlawful' Knockoffs Will Pressure Wegovy
The company says it's working to ensure patients only receive semaglutide produced by Novo Nordisk. 
Via Investor's Business Daily
Topics Earnings
A Rough Day for "Dividend Knights"
Between battered industries and overlooked opportunities, plenty of dividend-paying companies have slipped. 
Via The Motley Fool
How To Earn $500 A Month From Eli Lilly Stock Ahead Of Q2 Earnings
Eli Lilly offers an annual dividend yield of 0.78%. So, how can investors exploit its dividend yield to pocket a regular $500 monthly? 
Via Benzinga
Novo Nordisk Edges Up Premarket As Q2 Wegovy Sales Defy Copycat Threats: Retail Stays Bullish Amid Tariff Pressure
The results follow Novo’s worst weekly decline in its history after the company slashed its full-year guidance. 
Via Stocktwits
Topics Government World Trade
Trump Threatens Pharma With Potential 250% Tariffs In 18 Months: 'We Want Pharmaceuticals Made In Our Country'
President Donald Trump has indicated the possibility of imposing tariffs on imported pharmaceuticals that could rise up to 250%, indicating the highest rate he has proposed so far. 
Via Benzinga
Topics Government World Trade
Eli Lilly Earnings: What To Look For From LLY
Global pharmaceutical company Eli Lilly (NYSE:LLY) will be reporting earnings this Thursday before the bell. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence World Trade
IPO Stock Hinge Health Surges Despite Lackluster Second-Quarter Sales
The company, which went public in May, provides AI-powered physical therapy through a mobile application. 
Via Investor's Business Daily
Topics Initial Public Offering
Inspire Medical Plunges On Outlook Cut, Weak V System Rollout: Analysts React
Inspire Medical stock falls as Q2 earnings beat is overshadowed by guidance cut and slower U.S. rollout of its newly approved Inspire V system. 
Via Benzinga
Topics Earnings
Why Novo Nordisk Stock Is Down Again Today
Are you brave enough to catch this falling knife? 
Via The Motley Fool
The 8 Best Stocks to Buy Now in August (2025)
Whether you're looking for growth stocks, dividend stocks, or artificial intelligence stocks, there is something for you in this incredible list. 
Via The Motley Fool
Topics Artificial Intelligence
Inspire Medical Systems Crashes 32% As Eli Lilly's GLP-1 Weighs On Guidance
The company makes implantable devices for sleep apnea, an area Eli Lilly is marketing its weight-loss drug. 
Via Investor's Business Daily
Novo Nordisk Stock Sinks—But Is a Bottom Finally In?
Novo Nordisk stock is down over 43% in 2025 as investors weigh weak guidance, GLP-1 competition, and the potential for a rebound after earnings 
Via MarketBeat
Eli Lilly Reverses Early Weakness, Closes Near Day's High After Key Trading Signal
A significant trading signal flashed for Eli Lilly (LLY) at a price of $755.87, after which LLY rose up to 1.8% and closed near its intra-day high. 
Via Benzinga
Hims & Hers Health Stock Plunges Over 13% In Tuesday Pre-Market: What's Going On?
Hims & Hers Health Inc. (NYSE: HIMS) plunged 13.1% in Tuesday pre-market after the digital health company reported second-quarter revenue on Monday that missed Wall Street expectations. 
Via Benzinga
Prediction: This Unstoppable Growth Stock Will Be Worth $2 Trillion in the Next 7 Years
It's not too late to invest in this company. 
Via The Motley Fool
Spotlight on Eli Lilly: Analyzing the Surge in Options Activity
 
Via Benzinga
This Biotech Stock Could Soar on Upcoming Clinical Data
This weight loss drugmaker may be significantly undervalued right now. 
Via The Motley Fool
Stock Market Today: US Stocks Likely To Open Higher Despite Weak Jobs Report—Palantir, Vertex Pharma In Focus
US stock futures are up on Monday after ending Friday deep in the red, following a disappointing jobs report by Bureau of Labor Statistics. 
Via Benzinga
Pfizer's Ascent Signals Broader Health Sector Resilience Amidst Innovation Wave
In a notable shift, shares of Pfizer (NYSE: PFE) have recently edged higher, reflecting a burgeoning strength within the broader health sector. This uptick signals a renewed investor confidence in the... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
3 Unstoppable Stocks to Buy in August
Here are hot stocks to buy in a hot month. 
Via The Motley Fool
Topics Intellectual Property
Why Eli Lilly Stock Topped the Market Today
Zepbound could benefit handsomely if an apparently planned government program is implemented. 
Via The Motley Fool
Topics Government
Why Novo Nordisk Stock Bumped Higher on Friday
There might be a new way for certain users to defray their costs for obesity treatments. 
Via The Motley Fool
Topics Government
Pheton Holdings Dismisses Rumors Of Acquisition By Gilead, But Retail’s Extremely Optimistic
pheton-holdings-dismisses-rumors-of-acquisition-by-gilead 
Via Stocktwits
Topics Government
Eli Lilly, Novo Nordisk Shares Rally As Trump Administration Reportedly Plans To Experiment Including Weight-loss Drugs Under Medicaid, Medicare
The Washington Post reported on Friday that state Medicaid programs and Medicare Part D insurance plans will be able to voluntarily choose to cover Ozempic, Wegovy, Mounjaro, and Zepbound for patients... 
Via Stocktwits
Topics Government
Trump Administration Plan Signals Shift Toward Weight-Loss Drug Coverage For Medicare Patients
The Trump administration is planning a five-year test allowing states to cover weight-loss drugs like Ozempic and Wegovy under Medicare and Medicaid programs. 
Via Benzinga
Topics Government
3 Dividend Healthcare Stocks to Buy Hand Over Fist Before They Double
These pharmaceutical giants are well worth a second look. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.